{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-130553","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2024-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.854393+00:00","generated_at":"2026-05-29T18:40:02.484714+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Enanta reports FY2024 revenue $67.6M, net loss $116M; RSV & immunology pipelines advance","bullets":["Q4 revenue $14.6M (down 23% YoY); full-year $67.6M vs $79.2M due to lower MAVYRET royalties.","Net loss Q4 $28.8M ($1.36/shr); full-year $116.0M ($5.48/shr) vs $133.8M prior year.","Cash & securities $248.2M at Sept 30, 2024; runway expected into fiscal 2027.","RSVPEDs zelicapavir Phase 2 topline data due December 2024; EDP-323 Phase 2a met endpoints (p<0.0001).","Immunology expansion: KIT inhibitor EPS-1421 nominated; new STAT6 discovery program initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-130553","json":"https://secwatch.observer/filing/0000950170-24-130553.json","markdown":"https://secwatch.observer/filing/0000950170-24-130553.md","text":"https://secwatch.observer/filing/0000950170-24-130553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024130553/0000950170-24-130553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024130553/enta-20241125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T18:40:02.484714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}